Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: The ANRS CO13 HEPAVIH cohort

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 351-358

  Marcellin, Fabienne ^a,b,c   Roux, Perrine ^a,b,c   Winnock, Maria ^d,e   Lions, Caroline ^a,b,c   Dabis, François ^d,e   Salmon Ceron, Dominique ^f,g   Loko, Marc Arthur ^d,e   Spire, Bruno ^a,b,c   Carrieri, Maria Patrizia ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSERM   (France)

^f Service des Maladies Infectieuses et Tropicales Hôpital Cochin AP HP ^*  (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

co infection; hepatitis C virus; HIV; patient reported outcomes; peg interferon; ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; FALDAPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ALCOHOL ABUSE; ANGER; ARTICLE; BEHAVIOR DISORDER; CACAO; COFFEE; COGNITIVE DEFECT; DEPRESSION; FATIGUE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PROTECTION; MEDICATION COMPLIANCE; MIXED INFECTION; SELF REPORT; VIRUS LOAD; CLINICAL TRIAL (TOPIC); COINFECTION; COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; SELF REPORT;

EID: 84899011319     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.888949     Document Type: Article

References (57)

1. Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010;85(1):303-15
2. Smit C, van den Berg C, Geskus R, et al. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008;47(2): 221-5 (Pubitemid 351172190)
3. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52(7): 1035-40 (Pubitemid 36765298)
4. Rodri'guez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Curr Opin Infect Dis 2013;26(1):50-7
5. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009;83(15):7366-74
6. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283(1):74-80 (Pubitemid 30038386)
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatol Baltim Md 2002;36(5 Suppl 1):S237-44 (Pubitemid 35253486)
8. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66(1):41-8
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
10. Marcellin P, Asselah T. Viral hepatitis: impressive advances but still a long way to eradication of the disease. Liver Int 2014; 34(Suppl 1):1-3
11. Rockstroh JK, Bhagani S. Managing HIV/ hepatitis C co-infection in the era of direct acting antivirals. BMC Med 2013;11:234
12. Poizot-Martin I, Merchadou L, Carrieri P, et al. Access to HCV triple therapy with telaprevir or boceprevir in real-life setting in HIV-HCV co-infected patients - ANRS CO13 Hepavih Cohort (France), 7th IAS conference on HIV pathogenesis, treatment and prevention, 30 June-3 July 2013, Kuala Lumpur, Malaysia (abstract TUAB0102).
13. Martel-Laferriere V, Dieterich DT. Treating HCV in HIV 2013: on the cusp of change. Liver Int 2014;34(Suppl 1):53-9
14. Braitstein P, Montessori V, Chan K, et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005; 17(4):505-15 (Pubitemid 40663210)
15. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013;57(Suppl 2): S105-10
16. Martin TCS, Martin NK, Hickman M, et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS 2013;27(16): 2551-7
17. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57(Suppl 2):S80-9
18. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004;25(6):535-52 (Pubitemid 39592859)
19. Marcellin F, Carrieri MP, Spire B. Choice of therapeutic strategies in the context of HIV infection: key role of patient-reported outcomes. Expert Rev Anti Infect Ther 2012;10(4):403-6
20. Loko M-A, Salmon D, Carrieri P, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings. 2006-2010. BMC Infect Dis 2010;10:303
21. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28(3):805-9 (Pubitemid 28405433)
22. Romero-Gomez M, Grande L, Nogales MC, et al. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001;33(8): 698-702 (Pubitemid 33107671)
23. Adeyemi OM. Hepatitis C in HIV-positive patients-treatment and liver disease outcomes. J Clin Gastroenterol 2007;41(1): 75-87
24. Samet JH, Horton NJ, Meli S, et al. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 2004;28(4):572-7 (Pubitemid 38506891)
25. Shuper PA, Neuman M, Kanteres F, et al. Causal considerations on alcohol and HIV/ AIDS-a systematic review. Alcohol Alcohol 2010;45(2):159-66
26. Bohn MJ, Babor TF, Kranzler HR. The Alcohol use disorders identification test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995;56(4):423-32
27. Marcellin F, Lions C, Winnock M, et al. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort). Addiction 2013;108(7): 1250-8
28. Heeb J-L, Gmel G. Measuring alcohol consumption: a comparison of graduated frequency, quantity frequency, and weekly recall diary methods in a general population survey. Addict Behav 2005;30(3):403-13 (Pubitemid 40249395)
29. Roux P, Cohen J, Lascoux-Combe C, et al. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. Drug Alcohol Depend 2011;116(1-3): 228-32
30. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction 2003;98(Suppl 2):1-12 (Pubitemid 38030757)
31. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012;55(suppl 1):S33-42
32. Sulkowski M, Cheever I, Spach D. A guide for evaluation and treatment of Hepatitis C in adults coinfected with HIV. Department of Health and Human Services; Health Resources and Services Administration; Washington, DC, USA: 2011
33. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013;57(4):1325-32
34. Salmon-Ceron D, Cohen J, Winnock M, et al. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort. France). BMC Health Serv Res 2012;12:59
35. Marcellin F, Pre'au M, Dellamonica P, et al. Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage 2007;34(4):413-21 (Pubitemid 47454702)
36. Kemmer N, Hua L, Andersen JW, et al. Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study. J Viral Hepat 2012; 19(11):792-800
37. Mandorfer M, Payer BA, Scheiner B, et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int 2014;34(1):69-77
38. Roux P, Fugon L, Winnock M, et al. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction 2012;107(1):152-9
39. Roux P, Lions C, et al. The ANRS CO 13 HEPAVIH Study Group. Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther 2013. Available from: www. intmedpress.com/journals/avt/abstract.cfm? id=2699&pid=48
40. Marcellin F, Cohen J, Salmon D, et al. Addictive behaviors and hepatitis C virus (HCV) clearance following treatment: exploratory study among HIV-HCV coinfected patients (ANRS CO13 HEPAVIH), 11th International AIDS Impact Conference, 29 September-2 October 2013, Barcelona (Abstract 264)
41. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9(4):295-303 (Pubitemid 36002465)
42. Co-infections. Fighting fatigue and depression in HCV/HIV co-infection. Treatmentupdate 2006;18(1):2-3
43. Marcellin F, Preau M, Ravaux I, et al. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007;8(5):320-7 (Pubitemid 350103429)
44. Michel L, Villes V, Dabis F, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008. J Viral Hepat 2010; 17(9):650-60
45. Fuhrer R, Rouillon F. La version française de l'e'chelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatr Psychobiol 1989;4:163-6 (Pubitemid 19210689)
46. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(Suppl 1):S79-83 (Pubitemid 24023890)
47. Pre'au M, Marcellin F, Spire B, et al. Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients. J Clin Gastroenterol 2008;42(1):92-6
48. Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M. Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. J Hepatol 2012;56(3):745-7
49. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001;54(Suppl 1):S77-90 (Pubitemid 34013693)
50. Freedman ND, Curto TM, Lindsay KL, et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011;140(7):1961-9
51. Costentin CE, Roudot-Thoraval F, Zafrani E-S, et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011;54(6):1123-9
52. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132(5):1740-5 (Pubitemid 46677953)
53. Carrieri MP, Lions C, Sogni P, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol 2014;60(1):46-53
54. Carrieri MP, Sogni P, Cohen J, et al. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO- 13). Hepatology 2012;56(5):2010
55. Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 2005;100(6):1317-21 (Pubitemid 40904355)
56. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl 1):i36-46
57. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013;45(Suppl 5):S343-8